Multicenter Phase II study of erlotinib therapy in recurrent or advanced non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutatio

Phase 2

• Conditions: on small cell lung cancer with Epidermal Growth Factor Receptor mutation

• Registration Number: JPRN-UMIN000003270
• Lead Sponsor: ung Oncology Group in Kyushu, Japan (LOGIK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-03-01
• Study Completion: 2012-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis. 2)Patients with massive pleural or pericardial effusion ,or ascites. 3)Patients with active severe infections. 4)Cases with past history of administration of HER related agents. [ex) gefitinib, lapatinib, trsutuzumab, cetuximab] 5)Impossible cases with oral administration. 6)Patients with active opthalmological disease. 7) Patients with active concomitant malignancy. 8) Patients with symptomatic brain metastasis. 9)Patients with double cancer. 10)Patients with uncontrollabe diabetes mellitus. 11)Patients with uncontrollable complications. 12)Inappropriate patients for this study judged by the physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified